CD8A and liver cancer: Furthermore, when CD8+ TILs from human liver cancers were treated with TIGIT and PD-1-blocking mAbs, the coblockade of TIGIT and PD1 significantly improved the expansion, cytokine production, and cytotoxicity of CD8+ TILs compared with single PD-1 blockade (126).